Fully automated synthesis of [18F]fluoro‐dihydrotestosterone ([18F]FDHT) using the FlexLab module |
| |
| Authors: | Uwe Ackermann Jason S. Lewis Kenneth Young Michael J. Morris Andrew Weickhardt Ian D. Davis Andrew M. Scott |
| |
| Affiliation: | 1. Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Australia;2. Olivia Newton‐John Cancer Research Institute, Heidelberg, Australia;3. School of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Australia;4. School of Cancer Medicine, LaTrobe University, Australia;5. Radiochemistry & Molecular Imaging Probe Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA;6. Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;7. Monash University Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia;8. Eastern Health, Melbourne, Australia |
| |
| Abstract: | Imaging of androgen receptor expression in prostate cancer using F‐18 FDHT is becoming increasingly popular. With the radiolabelling precursor now commercially available, developing a fully automated synthesis of [18F] FDHT is important. We have fully automated the synthesis of F‐18 FDHT using the iPhase FlexLab module using only commercially available components. Total synthesis time was 90 min, radiochemical yields were 25‐33% (n = 11). Radiochemical purity of the final formulation was > 99% and specific activity was > 18.5 GBq/µmol for all batches. This method can be up‐scaled as desired, thus making it possible to study multiple patients in a day. Furthermore, our procedure uses 4 mg of precursor only and is therefore cost‐effective. The synthesis has now been validated at Austin Health and is currently used for [18F]FDHT studies in patients. We believe that this method can easily adapted by other modules to further widen the availability of [18F]FDHT. |
| |
| Keywords: | |
|
|
